Home

David Hallal

CIK 1457477 · Chief Executive Officer · last filed 2026-06-04

David Hallal is a Chief Executive Officer who has filed 115 SEC Form 4 insider transactions across 5 companies since 2018. The most recent filing, for KLRS, was dated Jun 4, 2026. Across all open-market trades the lifetime net is −$16.8M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $102.9M across reported positions. 68 SEC filings were submitted jointly with ALEXION PHARMACEUTICALS, INC.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$102.87M

Companies

5

Total Filings

115

Lifetime Open-Market Net

-$16.84M

Filer Profile

Reported Address
C/O ALEXION PHARMACEUTICALS, INC
352 KNOTTER DRIVE
CHESHIRE, CT 06410
Related Filers
ALEXION PHARMACEUTICALS, INC. — 68 joint filings, latest 2016-08-10
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
KLRS Director — $3.38 — $0 2 2026-06-04
SRRK Chief Executive Officer 1,844,034 $55.41 $102.18M -$3.97M 15 2026-04-20
iTeos Therapeutics, Inc. (ITOS) Delisted Director 0 $10.15 $0 -$3.94M 9 2025-08-29
SEER Director 355,128 $1.95 $692.5K $0 5 2024-06-14
Kalaris Therapeutics, Inc. (ALVR) Delisted Director 99,210 $9.81 $973.3K -$8.93M 15 2024-06-07

Recent Filings

115 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-04 KLRS Grant (A) — $0 EDGAR
2026-04-20 SRRK Sell (S) −30,615 -$1.52M EDGAR
2026-02-11 SRRK Grant (A) +128,004 $0 EDGAR
2026-01-15 SRRK Sell (S) −57,450 -$2.45M EDGAR
2025-10-09 SRRK Gift (G) −205,000 $0 EDGAR
2025-08-29 iTeos Therapeutics, Inc. (ITOS) Delisted Disp (D) — $0 EDGAR
2025-06-06 iTeos Therapeutics, Inc. (ITOS) Delisted Notice (144) −38,228 -$391.5K EDGAR
2025-06-06 iTeos Therapeutics, Inc. (ITOS) Delisted Mixed — -$671.3K EDGAR
2025-06-05 iTeos Therapeutics, Inc. (ITOS) Delisted Notice (144) −38,227 -$388.1K EDGAR
2025-06-04 iTeos Therapeutics, Inc. (ITOS) Delisted Notice (144) −38,227 -$384.8K EDGAR
Showing 1–10 of 115
Page 1 of 12
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.